Literature DB >> 28588876

Increased risk for metachronous gastric adenocarcinoma following gastric MALT lymphoma-A US population-based study.

Carolina Palmela1, Cristina Fonseca2, Rita Faria3, Rute Baeta Baptista4, Sofia Ribeiro5, Alexandre Oliveira Ferreira1.   

Abstract

BACKGROUND: Gastric mucosa-associated lymphoid tissue lymphoma (gMALT) and gastric adenocarcinoma (GC) are long-term complications of chronic Helicobacter pylori (HP) gastritis. Treatment of HP infection induces remission in most patients with gMALT. Endoscopic follow-up is not currently endorsed after complete remission. However, the risk of GC in these patients is unclear.
OBJECTIVE: The objective of this study is to estimate GC risk in gMALT patients.
METHODS: The National Cancer Institute Surveillance, Epidemiology and End Results 13 (SEER) database-Nov 2014 Sub (1992-2012) was used to identify adult patients diagnosed with gMALT between 1992 and 2012. The standardized incidence ratio of second primary GC after a latency period of 12 months was calculated and compared to a reference SEER cohort of identical age, sex and time period. The risk of GC in these patients was also stratified by latency period (five years) and age.
RESULTS: We identified 2195 cases of gMALT lymphoma, and 20 (0.91%) of them subsequently developed GC with a relative risk (RR) of 4.32 (95% CI 2.64-6.67) compared to the American population. The median latency time was five years and the risk was maintained afterward (RR 4.92, 95% CI 2.45-8.79). When stratified by age group the risk was highest for the 45-64 group (RR 14.04, 95% CI 5.64-28.93).
CONCLUSION: gMALT lymphoma is associated with an increased risk of metachronous gastric adenocarcinoma. The risk is still present after more than five years of follow-up. Further studies may clarify the most adequate follow-up strategy.

Entities:  

Keywords:  Gastric MALT lymphoma; Helicobacter pylori; follow-up studies; gastric adenocarcinoma; metachronous cancer risk

Year:  2016        PMID: 28588876      PMCID: PMC5446146          DOI: 10.1177/2050640616671643

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  35 in total

Review 1.  Helicobacter pylori and MALT lymphoma.

Authors:  Pedro Farinha; Randy D Gascoyne
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

2.  Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  E Zucca; C Copie-Bergman; U Ricardi; C Thieblemont; M Raderer; M Ladetto
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

3.  Pathological disorders of the gastric mucosa surrounding carcinomas and primary lymphomas.

Authors:  J Arista-Nasr; F Jiménez-Rosas; N Uribe-Uribe; R Herrera-Goepfert; M Lazos-Ochoa
Journal:  Am J Gastroenterol       Date:  2001-06       Impact factor: 10.864

Review 4.  Synchronous gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma in association with Helicobacter pylori infection: comparing reported cases between the East and West.

Authors:  A O Chan; K M Chu; S T Yuen; S Y Leung; S K Lam; J Wong
Journal:  Am J Gastroenterol       Date:  2001-06       Impact factor: 10.864

5.  Incidence of second neoplasms in patients with MALT lymphoma: no increase in risk above the background population.

Authors:  W Y Au; R D Gascoyne; N Le; D S Viswanatha; R J Klasa; R Gallagher; J M Connors
Journal:  Ann Oncol       Date:  1999-03       Impact factor: 32.976

Review 6.  Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma.

Authors:  J P Gisbert; X Calvet
Journal:  Aliment Pharmacol Ther       Date:  2011-09-15       Impact factor: 8.171

7.  Synchronous and metachronous primary gastric lymphoma and adenocarcinoma: a clinicopathological study of 12 patients.

Authors:  S Nakamura; K Aoyagi; S Iwanaga; T Yao; M Tsuneyoshi; M Fujishima
Journal:  Cancer       Date:  1997-03-15       Impact factor: 6.860

8.  Incidence of gastric B-cell lymphomas: a population-based study in Germany.

Authors:  A Ullrich; W Fischbach; M Blettner
Journal:  Ann Oncol       Date:  2002-07       Impact factor: 32.976

9.  Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series.

Authors:  W Fischbach; M E Goebeler; A Ruskone-Fourmestraux; T Wündisch; A Neubauer; M Raderer; A Savio
Journal:  Gut       Date:  2007-07-16       Impact factor: 23.059

10.  Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group.

Authors:  E Bayerdörffer; A Neubauer; B Rudolph; C Thiede; N Lehn; S Eidt; M Stolte
Journal:  Lancet       Date:  1995-06-24       Impact factor: 79.321

View more
  4 in total

1.  Primary Gastrointestinal Follicular Lymphomas: A Prospective Study of 31 Patients with Long-term Follow-up Registered in the French Gastrointestinal Lymphoma Study Group (GELD) of the French Federation of Digestive Oncology (FFCD).

Authors:  Tamara Matysiak-Budnik; Philippe Jamet; Nicolas Chapelle; Bettina Fabiani; Paul Coppo; Agnès Ruskoné-Fourmestraux
Journal:  Gut Liver       Date:  2022-03-15       Impact factor: 4.519

Review 2.  Endoscopic features aiding the diagnosis of gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Byung Sam Park; Si Hyung Lee
Journal:  Yeungnam Univ J Med       Date:  2019-02-26

3.  Inhibition of protein FAK enhances 5-FU chemosensitivity to gastric carcinoma via p53 signaling pathways.

Authors:  Jingjing Hou; Yuyu Tan; Chen Su; Tao Wang; Zhixing Gao; Dan Song; Jiabao Zhao; Yueting Liao; Xiaotian Liu; Ying Jiang; Qian Feng; Zhong Wan; Yongsheng Yu
Journal:  Comput Struct Biotechnol J       Date:  2019-12-30       Impact factor: 7.271

4.  Second Primary Cancers After Gastric Cancer, and Gastric Cancer as Second Primary Cancer.

Authors:  Guoqiao Zheng; Kristina Sundquist; Jan Sundquist; Tianhui Chen; Asta Försti; Akseli Hemminki; Kari Hemminki
Journal:  Clin Epidemiol       Date:  2021-07-02       Impact factor: 4.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.